CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 606 enrolled
Drug / intervention
DU-176bdrug
Likely dose
Not stated in record
Key inclusion· 1
  • ✓Unilateral hip replacement
Key exclusion· 9
  • ✕Bilateral hip replacement in same procedure
  • ✕Increased risk of bleeding
  • ✕Uncontrolled hypertension (BP >180/100 mmHg)
  • ✕Weight <111 lbs or >243 lbs

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00107900
NCT00107900Phase 2Completed
CompareCT.gov

A Phase IIa, Multi-center, Multi-national, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty

Daiichi Sankyo·interventional·Posted Apr 12, 2005·Updated Feb 26, 2019

In Brief

A Phase 2 clinical trial evaluating DU-176b for Arthroplasty, Replacement, Hip and Thrombosis. Completed, enrolled 606 participants across 1 site.

Detailed Summary

Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the occurrence of deep vein thrombosis in patients having total hip replacement surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthroplasty, Replacement, Hip, Thrombosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 12, 2005
Enrollment StartJan 1, 2005
Primary CompletionDec 1, 2005
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 21.2 years ago

Interventions

DU-176bdrug